GILD
$60.86
Gilead Sciences
($.27)
(.44%)
GILD
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  $1.79
Revenue:  $6.62 Bil
Wednesday
Jan 27
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when GILD reports earnings?
Beat
Meet
Miss

Where is GILD's stock price going from here?
Up
Flat
Down
Stock chart of GILD
Analysts
Summary of analysts' recommendations for GILD
Score
Grade
Pivots
Resistance
$62.39
$61.96
$61.41

$60.98

Support
$60.43
$60.00
$59.45
Tweet
Growth
Description
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. Their portfolio of marketed products includes a number of category firsts, including complete treatment regimens for HIV infection available in a once-daily single pill and the first oral antiretroviral pill available to reduce the risk of acquiring HIV infection in certain high-risk adults.
Peers
BiogenAmgenNeurocrine BiosciencesSeattle GeneticsBluebird BioQiagen N.V.Bio-TechneRepligenBioCryst PharmaceuticalsNovavax